Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.
Wen-Xian WangQian WangChun-Wei XuZiming LiZhengbo SongYong-Chang ZhangXiuyu CaiShirong ZhangBin LianWen LiAnwen LiuPing ZhanHongbing LiuTangfeng LvLi-Yun MiaoLingfeng MinYu ChenJingping YuanFeng WangZhansheng JiangGen LinXingxiang PuChuangzhou RaoDongqing LvZongyang YuXiaoyan LiChuanhao TangCheng-Zhi ZhouCongying XieJunping ZhangHui GuoQian ChuRui MengJingxun WuRui ZhangLiping WangYoucai ZhuXiao HuYanru XieXinqing LinJing CaiFen LanHuijing FengLin WangWang YaoXuefei ShiJianhui HuangHuafei ChenYinbin ZhangPingli SunBing WanFei PangZanmei XuKai WangYuanli XiaMingxiang YeDong WangQing WeiShuitu FengJianya ZhouJiexia ZhangDonglai LvWenbin GaoJing KangGenhua YuXianbin LiangChengtao YuLin ShiNong YangLin WuZhuan HongWei HongMeiyu FangYiping ZhangYuanzhi LuGuansong WangShenglin MaLu SiWenfeng FangYong SongPublished in: Thoracic cancer (2022)
Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.